LRRK2 in Parkinson's disease: Genetic and clinical studies from patients

FEBS Journal

Volumn 276, Issue 22, 2009, Pages 6455-6463

  Kumari, Udhaya ^a,b   Tan, E K ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

LRRK2; Mutations; Parkinson's disease; Penetrance; Polymorphisms

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; LEUCINE RICH REPEAT KINASE 2; RAS PROTEIN;

ARAB; ASIAN; CLINICAL FEATURE; CODON; ETHNIC GROUP; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; JEW; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RISK; SHORT SURVEY;

GENETIC TESTING; GENOTYPE; HUMANS; MUTATION; PARKINSON DISEASE; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES;

EID: 70350447105     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07344.x     Document Type: Short Survey

References (56)

1. Gandhi PN, Chen SG Wilson-Delfosse AL (2009) Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res 87, 1283 1295.
2. Santpere G Ferrer I (2009) LRRK2 and neurodegeneration. Acta Neuropathol 117, 227 246.
3. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S Obata F (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51, 296 301.
4. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601 607.
5. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595 600.
6. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365, 410 412.
7. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N et al. (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365, 412 415.
8. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415 416.
9. Tan EK Skipper LM (2007) Pathogenic mutations in Parkinson disease. Hum Mutat 28, 641 653.
10. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P Brice A (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354, 422 423.
11. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354, 424 425.
12. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A Alessi DR (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405, 307 317.
13. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329 341.
14. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7, 583 590.
15. Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, Weng YH, Rohe CF, Breedveld GJ, Hattori N et al. (2005) The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord 11, 521 522.
16. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y et al. (2005) The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 384, 327 329.
17. Tan EK (2006) Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Ann Acad Med Singapore 35, 840 842.
18. Bar-Shira A, Hutter CM, Giladi N, Zabetian CP Orr-Urtreger A (2009) Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. Neurogenetics doi :.
19. Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A Brice A (2005) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77, 330 332.
20. Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS et al. (2006) LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79, 752 758.
21. Tan EK, Skipper L, Tan L Liu JJ (2007) LRRK2 G2019S founder haplotype in the Chinese population. Mov Disord 22, 105 107.
22. Zabetian CP, Morino H, Ujike H, Yamamoto M, Oda M, Maruyama H, Izumi Y, Kaji R, Griffith A, Leis BC et al. (2006) Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 67, 697 699.
23. Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, Ragone L, Pahwa R, Jankovic J, Nance M et al. (2008) A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord 14, 77 80.
24. Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R et al. (2005) LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett 382, 309 311. (Pubitemid 40733642)
25. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH Griffith A (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65, 741 744.
26. Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S et al. (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70, 1456 1460.
27. Gorostidi A, Ruiz-Martinez J, Lopez de Munain A, Alzualde A Marti Masso JF (2009) LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 10, 157 159.
28. Simon-Sanchez J, Marti-Masso JF, Sanchez-Mut JV, Paisan-Ruiz C, Martinez-Gil A, Ruiz-Martinez J, Saenz A, Singleton AB, Lopez de Munain A Perez-Tur J (2006) Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord 21, 1954 1959.
29. Mata IF, Hutter CM, Gonzalez-Fernandez MC, de Pancorbo MM, Lezcano E, Huerta C, Blazquez M, Ribacoba R, Guisasola LM, Salvador C et al. (2009) Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics doi :.
30. Ross OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K, Latsoudis H, Plaitakis A, Ferreira JJ, Sampaio C et al. (2009) Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord 15, 466 467.
31. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J Ashizawa T (2000) Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55, 533 538.
32. Skipper L, Li Y, Bonnard C, Pavanni R, Yih Y, Chua E, Sung WK, Tan L, Wong MC, Tan EK et al. (2005) Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Hum Mol Genet 14, 3549 3556.
33. Biskup S, Mueller JC, Sharma M, Lichtner P, Zimprich A, Berg D, Wullner U, Illig T, Meitinger T Gasser T (2005) Common variants of LRRK2 are not associated with sporadic Parkinson's disease. Ann Neurol 58, 905 908.
34. Paisan-Ruiz C, Evans EW, Jain S, Xiromerisiou G, Gibbs JR, Eerola J, Gourbali V, Hellstrom O, Duckworth J, Papadimitriou A et al. (2006) Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium. J Med Genet 43, e9.
35. Paisan-Ruiz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St George-Hyslop P, Singleton A Rogaeva E (2005) LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65, 696 700.
36. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS et al. (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171 177.
37. Tan EK (2007) The role of common genetic risk variants in Parkinson disease. Clin Genet 72, 387 393.
38. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N et al. (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7, 133 138.
39. Tan EK Schapira AH (2008) Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant. Eur J Neurol 15, 203 204.
40. Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, Ross OA Wu RM (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 13, 89 92.
41. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S, Chua E, Yuen Y et al. (2007) The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120, 857 863.
42. Tan EK, Lee J, Chen CP, Wong MC Zhao Y (2009) Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease. Neurobiol Aging 30, 501 502.
43. Tan EK, Fook-Chong S Yi Z (2007) Comparing LRRK2 Gly2385Arg carriers with noncarriers. Mov Disord 22, 749 750.
44. Tan EK, Peng R, Wu YR, Wu RM, Wu-Chou YH, Tan LC, An XK, Chen CM, Fook-Chong S Lu CS (2009) LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi-center pooled analysis. Am J Med Genet B Neuropsychiatr Genet 150B, 1022 1023.
45. Tan EK, Tan LC, Lim HQ, Li R, Tang M, Yih Y, Pavanni R, Prakash KM, Fook-Chong S Zhao Y (2008) LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. Hum Genet 124, 287 288.
46. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, Soto AI, Mata IF, Lee-Chen GJ, Chen CM, Tang M et al. (2008) Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 64, 88 92.
47. Tan EK, Tang M, Tan LC, Wu YR, Wu RM, Ross OA Zhao Y (2008) Lrrk2 R1628P in non-Chinese Asian races. Ann Neurol 64, 472 473.
48. Lu CS, Wu-Chou YH, van Doeselaar M, Simons EJ, Chang HC, Breedveld GJ, Di Fonzo A, Chen RS, Weng YH, Lai SC et al. (2008) The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population. Neurogenetics 9, 271 276.
49. Nandhagopal R, Mak E, Schulzer M, McKenzie J, McCormick S, Sossi V, Ruth TJ, Strongosky A, Farrer MJ, Wszolek ZK et al. (2008) Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 71, 1790 1795.
50. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M et al. (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128, 2777 2785.
51. Schweitzer KJ, Brussel T, Leitner P, Kruger R, Bauer P, Woitalla D, Tomiuk J, Gasser T Berg D (2007) Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 254, 613 616.
52. Silveira-Moriyama L, Guedes LC, Kingsbury A, Ayling H, Shaw K, Barbosa ER, Bonifati V, Quinn NP, Abou-Sleiman P, Wood NW et al. (2008) Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology 71, 1021 1026.
53. Quattrone A, Bagnato A, Annesi G, Novellino F, Morgante L, Savettieri G, Zappia M, Tarantino P, Candiano IC, Annesi F et al. (2008) Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease. Mov Disord 23, 21 27.
54. Tan EK Jankovic J (2006) Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol 63, 1232 1237. (Pubitemid 44379821)
55. Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S Jankovic J (2007) Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci 252, 113 120.
56. Healy DG, Wood NW Schapira AH (2008) Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol 8, 381 385.